Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

Novo Nordisk reported mostly mild side effects from its experimental weight-loss drug CagriSema, though results upset ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Trials of a new drug for obesity and type 2 diabetes have seen patients lose 15pc of their body weight and return their blood ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...

Novo Nordisk has presented full Phase 3 trial results for CagriSema, an experimental weight-loss drug, revealing primarily ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the ...

Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type 2 ...